Bosutinib (Bosulif)

Bosutinib at a glance

Bosutinib, with the verified brand Bosulif, belongs to a group called tyrosine kinase inhibitors, or TKIs. It acts on growth signals within certain leukaemia cells. It is taken once daily with food, usually continuously rather than in cycles with planned treatment-free weeks.

Tablets and hard capsules are available in the reviewed sources. Their swallowing instructions differ: tablets must remain whole, while specified capsules can be opened and mixed with specified soft food when the pharmacist has explained the method. A capsule-opening method must never be assumed to apply to a tablet.

Diarrhoea, nausea, abdominal discomfort, rash and fatigue are familiar concerns, but blood, liver, kidney and heart effects also need attention. Feeling well does not replace monitoring. Keep your hospital's urgent contact details and an up-to-date list of medicines readily available.

What bosutinib is and how it works

A tyrosine kinase is a protein involved in passing signals inside cells. Bosutinib inhibits BCR–ABL and Src-family kinases. BCR–ABL is an abnormal growth signal associated with the Philadelphia chromosome, a change found in the leukaemia cells of many people with chronic myeloid leukaemia. Blocking this signal can reduce the growth of affected cells.

This is targeted therapy, not a checkpoint immunotherapy. The word targeted does not mean that healthy tissues are unaffected or that the medicine is suitable for every person. A treatment can be effective without causing obvious side effects, and troublesome side effects do not prove that it is working better.

The Philadelphia chromosome result describes the leukaemia cells. Ask your team to explain your test report and how it relates to treatment. The aim is to make the results understandable, rather than expecting you to interpret specialised chromosome or molecular measurements alone.

How the team decides whether it is suitable

The haematology team reviews the diagnosis, Philadelphia chromosome or BCR–ABL test results, disease features, previous medicines and reasons for any treatment change. If response is inadequate, additional testing, including mutation analysis in some circumstances, may help guide the next decision. Not every BCR–ABL change responds equally to every TKI.

Your other health conditions matter. Mention liver disease, hepatitis B, kidney problems, heart failure, previous heart attack, abnormal heart rhythm, persistent diarrhoea, pancreatitis and serious medicine allergies. Bring details of reflux treatments, supplements and medicines from every prescriber.

Liver impairment needs particular discussion because instructions differ by region. US information includes reduced starting doses for liver impairment; European information lists hepatic impairment as a contraindication. Do not assume that a lower dose automatically makes treatment appropriate. The specialist must follow the applicable product information and assess your individual situation.

Children require a specialist plan based on body size, organ function and the locally applicable formulation information. Adult doses should never be adapted at home for a child. This guide supports discussion and safe routines; it is not a paediatric dose calculator.

Before treatment starts

Baseline checks include a complete blood count, liver tests and kidney function. The team may also check electrolytes, including potassium and magnesium, and other blood chemistry. Low electrolyte levels, dehydration and a high uric acid level may need correction before treatment.

European information recommends an electrocardiogram, or ECG, before treatment and further checks when clinically needed. An ECG records the heart's electrical activity. Tell the team about fainting, palpitations or medicines that affect heart rhythm, even if they were prescribed for nausea or another unrelated problem.

Testing for hepatitis B before treatment is important. Previous infection may be relevant even when you feel well or were told years ago that it had settled. People with positive tests may need advice from a liver or infection specialist and a monitoring or antiviral plan.

When pregnancy is possible, pregnancy testing and contraception planning should happen before the first dose. Ask about fertility preservation before treatment begins if future parenthood matters to you. Also obtain written instructions for diarrhoea, missed doses, food and any acid-reducing medicines, so these decisions are not left until you feel unwell.

How to take bosutinib

Dose and food

Take the prescribed dose once daily with food, ideally at a consistent time. Adult starting prescriptions commonly use 400 mg or 500 mg daily according to the treatment situation and previous therapy. Kidney function, liver-related restrictions, response and side effects can change the plan. These doses are not interchangeable choices for the patient.

The team may reduce, interrupt or sometimes increase treatment after reviewing results. Ask for written instructions whenever the strength or number of tablets or capsules changes.

Tablets and capsules are handled differently

Swallow tablets whole with water. Do not cut, crush, break or chew them. Ask the pharmacist for help if swallowing is difficult; do not make a tablet slurry or put crushed tablets into a feeding tube. Avoid handling broken or crushed tablets.

Capsules can be swallowed whole. For patients unable to do this, the reviewed Bosulif instructions permit opening the required capsules and mixing all their contents with room-temperature applesauce or yogurt. Patients and caregivers should wear gloves when handling the capsules or preparing the mixture, then wash their hands afterwards. The pharmacist must confirm the number of capsules and specified food volume for your dose. Use only the instructed preparation; do not substitute a drink or another food without checking.

Consume the entire mixture immediately without chewing, and do not save it for later. The small amount of soft food is not a replacement for the meal required with treatment. If the whole preparation is not swallowed, do not give an additional dose; wait until the next day to resume dosing and tell the team what happened. Ask for specialist advice for a feeding tube.

Missed doses, vomiting and accidental extra doses

If you remember within 12 hours of the usual time, take the missed dose with food. If more than 12 hours have passed, skip it and take the next dose at its regular time the following day. Never double up. If timing is uncertain, ask the pharmacist rather than taking doses close together.

If you vomit after taking bosutinib, do not take an extra dose. Contact the treating team for advice, especially if vomiting continues or you cannot drink. Vomiting does not reliably show how much medicine was absorbed.

If too much is taken, contact the hospital or seek urgent medical assessment immediately. Keep the pack and details of the amount and time available. Do not wait for symptoms or try to compensate by improvising the following day's schedule.

Storage and supplies

Keep the medicine in its supplied packaging, away from children. US instructions specify room temperature, 20–25°C (68–77°F); capsules stay in the original bottle, and the desiccant in a tablet bottle must remain there and must not be eaten. Follow your own pack's instructions and ask about heat exposure during travel. Return unwanted medicine through the pharmacy or treatment service.

Monitoring and checking whether treatment is working

Blood counts are usually checked weekly during the first month and monthly afterwards, or more often when clinically needed. These identify low infection-fighting cells, red cells or platelets before complications develop. Attend checks even when symptoms are mild or absent.

Liver enzyme testing is required at least monthly for the first three months and subsequently as needed. Abnormal results can require closer testing, a pause or a change in treatment. Kidney function is checked before and during therapy because it can decline over time; dehydration and other medicines can add to the problem.

The team also checks symptoms, weight, fluid retention and cardiovascular health. An ECG or other heart tests may be repeated when the history, examination or symptoms suggest a need. Ask whether to record your weight or blood pressure at home; there is no single home-monitoring schedule for everyone.

Treatment response is assessed through blood counts and specialised tests measuring leukaemia, such as BCR–ABL molecular testing. A normal routine blood count is not the same as a deep molecular response. Ask what result is being tracked, what the target means and when the next assessment is due. Do not stop treatment because one result looks reassuring.

Common side effects and practical management

Diarrhoea

Loose stools often begin early, sometimes within the first few days. Keep a record of frequency, urgency, night-time symptoms and any blood or pain. Use anti-diarrhoea medicine only as instructed, and contact the team early if stools are repeatedly loose, increasing or disrupting drinking and daily activities.

Take frequent drinks unless you have a fluid restriction, and ask whether an oral rehydration solution is appropriate. Small, tolerable meals may be easier than a large meal. The team can assess infection, dehydration and electrolyte loss; severe diarrhoea may need a treatment pause or intravenous fluids, not simply stronger self-treatment.

Get urgent advice for blood in stools, fever, severe pain, dizziness, little urine or inability to keep fluids down. Do not assume that all diarrhoea is a harmless expected effect. Inform the team if you use an oral contraceptive pill, as severe diarrhoea can affect its absorption.

Nausea, appetite changes and abdominal discomfort

Take prescribed anti-sickness medicine as directed and ask for review if it is ineffective. Smaller meals and regular sips may help, but bosutinib still needs to be taken with food. Report falling intake, weight loss or ongoing vomiting. Anti-sickness choices need an interaction check; do not add an old prescription yourself.

Mild abdominal discomfort may occur, but persistent or severe pain requires assessment. Constipation can also happen. Ask before starting a laxative if pain, vomiting or a swollen abdomen is present. Reflux medicine needs particular care because some products reduce bosutinib absorption.

Rash and sun sensitivity

Tell the team about new itching, dryness or rash. Use gentle skin care and any recommended moisturiser, and protect skin with clothing and a high-protection sunscreen. Minimise strong sunlight and avoid tanning lamps. Do not assume an acne-like rash should be treated with harsh acne products.

Painful skin, blisters, peeling, mouth or eye sores, or a rash with fever needs urgent assessment. These are different from mild dryness and may signal a serious reaction.

Fatigue, headache and aches

Pace activities and allow rest, while keeping manageable movement if you feel able. Fatigue may reflect anaemia, infection, poor intake or another treatable problem, so report a marked change. Ask which painkillers are suitable for headache, muscle or joint discomfort; kidney function, bleeding risk and interactions affect that choice.

A new severe headache, fainting or neurological symptoms should not be managed as routine fatigue. Do not drive or use machinery when dizziness, sleepiness or impaired concentration makes it unsafe.

Less common but important side effects

Low blood counts and infection

Low neutrophils increase infection risk. Fever, shivering, a sore throat, cough, burning urine or sudden illness needs prompt advice. Infection can become serious quickly, and you may feel very unwell without a high temperature. Follow your hospital's fever threshold and urgent instructions.

Low platelets can cause bruising, nosebleeds or gum bleeding; report unusual bleeding promptly. Low red cells can cause breathlessness, pallor, palpitations and fatigue. Blood tests help distinguish these problems and guide treatment. Black stools, vomiting blood or bleeding that will not stop requires urgent assessment.

Liver injury and hepatitis B reactivation

Liver injury may first appear on tests. Yellow skin or eyes, dark urine, persistent nausea or pain in the upper right abdomen needs prompt medical advice. Do not add herbal liver remedies; they can introduce further toxicity or interactions.

Hepatitis B can become active again during BCR–ABL inhibitor treatment. Monitoring may continue for several months after bosutinib stops in people who carry the virus. Do not stop prescribed antiviral treatment without the specialist's advice, and keep appointments even if liver symptoms are absent.

Fluid retention and heart problems

Fluid can build up in the legs, around the lungs or heart, or elsewhere. New swelling, rapid weight gain, cough or breathlessness needs urgent review. Do not independently increase water tablets or severely restrict fluids; the cause and kidney function need assessment.

Lung inflammation has also been reported, so new cough or breathlessness must not be assumed to be fluid retention. Bosutinib can cause heart failure or reduced blood supply to the heart. Chest pain, severe breathlessness or collapse needs emergency care. New palpitations or faintness also needs urgent assessment, especially with vomiting or diarrhoea that may lower potassium or magnesium.

Kidney problems, pancreatitis and tumour lysis

Report a substantial change in urine amount or frequency, new swelling or worsening dehydration. Kidney changes may be detected only through blood tests. A small-blood-vessel disorder called thrombotic microangiopathy has been reported after marketing; unexplained bruising with marked weakness or reduced urine needs urgent assessment. Some painkillers and other medicines can increase kidney risk, so have them checked rather than assuming a familiar non-prescription medicine is safe.

Severe upper-abdominal pain, particularly with vomiting, can indicate pancreatitis and needs urgent assessment. Tumour lysis syndrome is another possible serious problem: breakdown of cancer cells can disturb blood chemistry and kidney function. The team assesses risk and may prescribe preventive measures. Severe weakness, muscle cramps, confusion, abnormal heartbeat or very little urine needs urgent help.

Severe skin or allergic reactions

A widespread blistering or peeling rash, painful mouth or eyes, or skin symptoms with fever requires immediate assessment. Swelling of the face, lips or tongue, wheezing, breathing difficulty or collapse may indicate a severe allergic reaction; call local emergency services. Do not try another dose to see whether the reaction happens again.

Other medicines, supplements and vaccinations

Bosutinib is affected by an enzyme called CYP3A. Strong or moderate inhibitors can increase its level and toxicity; examples include certain antifungals, antibiotics and antiviral medicines. Strong inducers, such as rifampicin, some seizure medicines and St John's wort, can lower exposure. These combinations generally need avoidance or an alternative arranged by the prescriber. European information also advises avoiding moderate inducers.

Avoid grapefruit, grapefruit juice and grapefruit-containing supplements. Tell the pharmacist about herbal, Ayurvedic and other complementary products without assuming that natural means interaction-free. Separating medicines by a few hours does not solve every enzyme interaction.

Acid-reducing medicines

Proton pump inhibitors, such as omeprazole, may reduce bosutinib absorption. Ask the team to review them rather than stopping a necessary medicine yourself. US information recommends short-acting antacids or H2 blockers as alternatives, with dosing separated by more than two hours from bosutinib. The US patient leaflet describes at least two hours before or after. Obtain an exact schedule from the pharmacist.

European information advises caution with proton pump inhibitors and separated short-acting antacids, for example morning versus evening. Do not assume that moving a proton pump inhibitor to another time reliably removes the interaction. Also check anti-sickness medicines and medicines affecting heart rhythm.

Ask about flu, COVID-19 and travel vaccines. Live vaccines may be unsuitable during immunosuppressive treatment; timing depends on blood counts and the complete treatment plan. Discuss planned vaccination with the haematology team rather than applying a universal waiting period.

Everyday life during treatment

Choose a meal-time routine that you can maintain, and use reminders if helpful. Check that repeat prescriptions arrive before supplies run out. Tell the team honestly about missed doses, difficulty paying for or obtaining supplies, and problems swallowing; these are practical issues they need to understand.

Plan travel around blood tests and access to urgent care. Carry medicines in their original packaging, bring the prescription and ask about time-zone changes. Keep a symptom diary that is brief enough to use: stool frequency, fever, swelling and missed doses are often more useful than trying to record everything.

Discuss work, exercise, intimacy and emotional wellbeing. Gentle activity can help some people manage fatigue, but new breathlessness or chest pain should be assessed. Tell dentists and other clinicians about treatment before procedures. Check alcohol use with the team, particularly if liver tests are abnormal or diarrhoea is causing dehydration.

Fertility, contraception, pregnancy and breastfeeding

Bosutinib can harm a developing baby. Use effective contraception if you can become pregnant, and report a possible pregnancy immediately. The post-treatment interval differs: US information specifies two weeks after the final dose, while European information specifies at least one month. Obtain a written plan for your product rather than choosing the shorter period.

Vomiting or diarrhoea can reduce absorption of an oral contraceptive pill. Ask promptly about additional or alternative protection. Do not assume the cancer medicine itself makes pregnancy impossible. The reviewed labels do not provide an equivalent specific male contraception interval; men should discuss conception planning with their specialist rather than copy the female interval.

Do not breastfeed during treatment. US information extends this to two weeks after the last dose; European information does not specify the same post-treatment interval. Ask when restarting is appropriate for your circumstances.

Animal findings suggest fertility may be reduced in females and males, but the effect in an individual person is uncertain. Discuss egg, embryo or sperm preservation before treatment when relevant. European information specifically advises men to seek advice about sperm conservation.

After treatment stops or changes

Continue blood tests and symptom monitoring until the team tells you otherwise. Recovery from low blood counts, liver changes or kidney problems may need follow-up. Hepatitis B carriers may need monitoring for several months after stopping. Keep contraception and breastfeeding precautions for the required interval.

Do not interpret an excellent molecular result as permission to stop on your own. Any planned treatment discontinuation requires specialist assessment and a defined monitoring programme. If treatment changes, ask exactly when to finish bosutinib, when to begin the next medicine and which interaction or safety instructions also change.

Return unwanted supplies and retain a record of the final dose, serious reactions and previous dose adjustments. Contact the team if delayed or persistent symptoms arise rather than assuming they cannot be related because treatment has ended.

Frequently asked questions